145 related articles for article (PubMed ID: 26928421)
41. Risk-reducing surgery in BRCA 1/2 mutation carries: a point of view.
De Felice F; Marchetti C
Oncotarget; 2015 Nov; 6(37):39391-2. PubMed ID: 26588056
[No Abstract] [Full Text] [Related]
42. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis.
Armstrong K; Schwartz JS; Randall T; Rubin SC; Weber B
J Clin Oncol; 2004 Mar; 22(6):1045-54. PubMed ID: 14981106
[TBL] [Abstract][Full Text] [Related]
43. Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy.
Garcia C; Lyon L; Conell C; Littell RD; Powell CB
Gynecol Oncol; 2015 Sep; 138(3):723-6. PubMed ID: 26086567
[TBL] [Abstract][Full Text] [Related]
44. Is Hormone Replacement Therapy Safe in Women With a BRCA Mutation?: A Systematic Review of the Contemporary Literature.
Birrer N; Chinchilla C; Del Carmen M; Dizon DS
Am J Clin Oncol; 2018 Mar; 41(3):313-315. PubMed ID: 26840041
[TBL] [Abstract][Full Text] [Related]
45. Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J; Lubinski J; Gronwald J; Cybulski C; Demsky R; Neuhausen SL; Kim-Sing C; Tung N; Friedman S; Senter L; Weitzel J; Karlan B; Moller P; Sun P; Narod SA;
Int J Cancer; 2015 Sep; 137(5):1136-46. PubMed ID: 25482078
[TBL] [Abstract][Full Text] [Related]
46. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
[TBL] [Abstract][Full Text] [Related]
47. Risk management options elected by women after testing positive for a BRCA mutation.
Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
[TBL] [Abstract][Full Text] [Related]
48. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing.
Skytte AB; Gerdes AM; Andersen MK; Sunde L; Brøndum-Nielsen K; Waldstrøm M; Kølvraa S; Crüger D
Clin Genet; 2010 Apr; 77(4):342-9. PubMed ID: 20059483
[TBL] [Abstract][Full Text] [Related]
49. A model for estimating ovarian cancer risk: application for preventive oophorectomy.
Giannakeas V; Sopik V; Shestopaloff K; Iqbal J; Rosen B; Akbari M; Narod SA
Gynecol Oncol; 2015 Nov; 139(2):242-7. PubMed ID: 26341709
[TBL] [Abstract][Full Text] [Related]
50. Postmenopausal hormone therapy in BRCA gene mutation carriers: to whom and which?
Grandi G; Caroli M; Cortesi L; Toss A; Tazzioli G; Facchinetti F
Expert Opin Drug Saf; 2020 Aug; 19(8):1025-1030. PubMed ID: 32648787
[TBL] [Abstract][Full Text] [Related]
51. Clinical Effects of Early or Surgical Menopause.
Kingsberg SA; Larkin LC; Liu JH
Obstet Gynecol; 2020 Apr; 135(4):853-868. PubMed ID: 32168205
[TBL] [Abstract][Full Text] [Related]
52. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.
Cibula D; Zikan M; Dusek L; Majek O
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1197-207. PubMed ID: 21916573
[TBL] [Abstract][Full Text] [Related]
53. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
[TBL] [Abstract][Full Text] [Related]
54. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
Arai M; Iwase T; Takazawa Y; Takeshima N
Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434
[TBL] [Abstract][Full Text] [Related]
55. Long-term health consequences of premature or early menopause and considerations for management.
Faubion SS; Kuhle CL; Shuster LT; Rocca WA
Climacteric; 2015; 18(4):483-91. PubMed ID: 25845383
[TBL] [Abstract][Full Text] [Related]
56. Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families.
Riahi A; Ghourabi ME; Fourati A; Chaabouni-Bouhamed H
Breast Cancer; 2017 Mar; 24(2):238-244. PubMed ID: 27025497
[TBL] [Abstract][Full Text] [Related]
57. Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers.
Menkiszak J; Chudecka-Głaz A; Gronwald J; Cymbaluk-Płoska A; Celewicz A; Świniarska M; Wężowska M; Bedner R; Zielińska D; Tarnowska P; Jakubowicz J; Kojs Z
J Ovarian Res; 2016 Feb; 9():11. PubMed ID: 26928677
[TBL] [Abstract][Full Text] [Related]
58. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers.
Kramer JL; Velazquez IA; Chen BE; Rosenberg PS; Struewing JP; Greene MH
J Clin Oncol; 2005 Dec; 23(34):8629-35. PubMed ID: 16314625
[TBL] [Abstract][Full Text] [Related]
59. Prophylactic oophorectomy in women at increased cancer risk.
Domchek SM; Rebbeck TR
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):27-30. PubMed ID: 17218848
[TBL] [Abstract][Full Text] [Related]
60. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT
Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
